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Abstract 
Transporter-mediated uptake determines the peak concentration, duration, and physical spread of 
released monoamines. Most studies of monoamine clearance focus on the presynaptic uptake1 transporters 
SERT, NET and DAT. However, recent studies have demonstrated the expression of the uptake2 transporter OCT3 
(organic cation transporter 3), throughout the rodent brain. In contrast to NET, DAT and SERT, OCT3 has higher 
capacity and lower affinity for substrates, is sodium-independent, and is multi-specific, with the capacity to 
transport norepinephrine, dopamine, serotonin and histamine. OCT3 is insensitive to inhibition by cocaine and 
antidepressant drugs but is inhibited directly by the glucocorticoid hormone corticosterone. Thus, OCT3 
represents a novel, stress hormone-sensitive, monoamine transport mechanism. Incorporating this transporter 
into current models of monoaminergic neurotransmission requires information on: A) the cellular and 
subcellular localization of the transporter; B) the effects of OCT3 inhibitors on monoamine clearance; and C) the 
consequences of decreased OCT3-mediated transport on physiology and/or behavior. This review summarizes 
studies describing the anatomical distribution of OCT3, its cellular and subcellular localization, its contribution to 
the regulation of dopaminergicsignaling, and its roles in the regulation of behavior. Together, these and other 
studies suggest that both Uptake1 and Uptake2 transporters play key roles in regulating monoaminergic 
neurotransmission and the effects of monoamines on behavior. 
1. Introduction 
Monoamines, including dopamine, serotonin, epinephrine and norepinephrine, exert powerful modulatory 
influences on brain function and behavior via actions mediated by receptors on neuronal and glial cells. The 
magnitude of released monoamine signals is determined not only by diffusion, but also by transporter-mediated 
clearance. Current models of dopamine signaling have suggested that dopamine concentration is primarily 
regulated by diffusion immediately surrounding release sites, but that transporter-mediated uptake determines 
the duration and physical spread of released monoamines (Rice and Cragg, 2008). Thus, uptake processes 
dictate the extent to which high- and low-affinity monoamine receptors are activated and, thus, the extent to 
which thousands of surrounding synapses are influenced. For these reasons, understanding the diversity and 
complexity of uptake processes is critical for a complete understanding of monoaminergic neurotransmission. 
Most studies of monoamine uptake have focused on the high-affinity sodium-dependent transporters which 
constitute the “Uptake1” family of monoamine transporters (DAT – dopamine transporter; NET 
– norepinephrine transporter; and SERT – serotonin reuptake transporter) and are expressed almost exclusively 
on the axon terminals of the monoamine releasing neurons. However, it has long been known that an “Uptake2” 
family of low-affinity, high-capacity transporters also contributes to monoamine clearance (Iversen, 1965). This 
review focuses on studies examining the localization of one uptake2 transporter, organic cation transporter 3 
(OCT3), and its roles in the regulation of dopaminergic neurotransmission and behavior. 
2. Catecholamine Uptake1 and Uptake2 
Early studies of catecholamine transport in heart tissue revealed the presence of two distinct uptake processes, 
termed uptake1 and uptake2, which differed in kinetic properties and sensitivity to inhibitors. Uptake1, a high-
affinity (Kd = 0.27 μM), low-capacity (Vmax = 1.22 nmol/min/g tissue) transport process, was inhibited by cocaine 
and desipramine. Uptake2, a low-affinity (Kd = 252 μM), high-capacity (Vmax = 100 nmol/min/g) process, while 
insensitive to cocaine and desipramine, was inhibited by normetanephrine and corticosterone(Iversen, 1965) 
(Iversen and Salt, 1970). Based on its low affinity, uptake2was originally believed to contribute to catecholamine 
clearance only when substrates were present at very high concentrations. However, subsequent studies 
demonstrated that uptake2 contributed to catecholamine clearance at all substrate concentrations (Lightman 
and Iversen, 1969). 
Uptake2-like activity has been attributed to at least four distinct transporters. These transporters, including 
the organic cation transporters (OCT1, OCT2, and OCT3) and the plasma membrane monoamine transporter 
(PMAT), all display high-capacity, bidirectional, sodium-independent transport of monoamines, with each 
transporter displaying a distinct substrate specificity profile for monoamines (Duan and Wang, 2010; Schomig et 
al., 2006). Although they were all (except for PMAT) originally described in peripheral tissues, all 
uptake2transporters have been detected in brain tissue (Amphoux et al., 2006; Engel et al., 2004). All are 
inhibited by corticosterone, although the sensitivity to corticosterone varies depending on the species examined 
and the tissue preparation used (reviewed in Koepsell et al. (2007)). Importantly, corticosterone-induced 
inhibition of OCT-mediated transport is rapid and involves direct interaction of the steroid with the transporter 
at specific sites (Volk et al., 2009). OCT3 is the most corticosteroid-sensitive, with IC50s in the physiological range 
for corticosterone (Gasser et al., 2006; Grundemann et al., 1998; Hill et al., 2011). This property positions OCT3 
as a critical mediator of stress and corticosteroid effects on neuronal and glial physiology and behavior 
independent of the glucocorticoid receptor (see Gasser and Lowry (2018)), for a review of OCT3 as a mediator of 
non-genomic corticosteroid actions). 
3. Cellular and subcellular localization of OCT3 
Understanding the roles of OCT3  in regulating monoaminergicneurotransmission and in mediating the effects 
of corticosterone on monoamine signaling and behavior requires knowledge of the regional, cellular and 
subcellular distribution of the transporter. Immunohistochemical studies with an OCT3-specific antibody have 
revealed that the transporter is expressed throughout the rat brain, with at least low levels of expression 
detected in nearly all brain regions (Gasser et al., 2009). The transporter is expressed in neurons (Cui et al., 
2009; Graf et al., 2013; Hill and Gasser, 2013; Shang et al., 2003; Vialou et al., 2004), including dopamine 
neurons (Mayer et al., 2018), and glial cells, including astrocytes (Cui et al., 2009; Gasser et al., 2017; Takeda et 
al., 2002) and microglia (He et al., 2017). It is also expressed in oligodendrocytes (Gasser et al., 
2009), ependymal cells (Gasser et al., 2006, 2009), and vascular endothelial cells in the brain (Li et al., 2013). The 
broad expression of this high-capacity monoamine transporter suggests that it plays an essential role in the 
regulation of extracellular monoamine concentrations in a variety of microenvironments. 
The degree to which OCT3-mediated transport activity determines the activation of 
monoamine receptors critically depends on the subcellular localization of the transporter, especially its 
proximity to monoamine release sites and receptors (Fig. 1). While there have been no studies directly 
examining the co-localization of OCT3 and monoamine release sites or receptors, a recent report described the 
subcellular localization of the transporter in rat brain using immuno-electron microscopy (Gasser et al., 2017). 
This study demonstrated OCT3 localization to plasma membranes of neuronal somata, as well as to dendritic and 
axonal profiles. OCT3 was also densely expressed in plasma membranes of astrocyte processes surrounding 
axodendritic and axospinous profiles. Positioned at these sites, OCT3-mediated transport may exert considerable 
influence over the duration and spread of released monoamines, and thus over the activation of monoamine 
receptors on both pre- and post-synaptic cells (Fig. 1). 
 
Fig. 1. Schematic model of the potential roles of OCT3-mediated transport, and its inhibition by corticosterone, in 
regulating monoamine signaling, and highlighting key outstanding questions regarding the localization and actions of 
OCT3. Monoaminergic terminals are depicted adjacent to a cell expressing plasma membrane receptors for monoamines 
under conditions of low (A) and high (B) concentrations of corticosterone. OCT3-mediated, high capacity monoamine 
transport is hypothesized to play important roles in regulating the duration and physical spread of released 
monoamines. A) The specific roles played by OCT3 in regulating monoaminergic transmission depend on the answers to key 
questions regarding 1) the localization of OCT3 with respect to monoamine release sites; 2) the proximity of OCT3 to 
monoamine receptors; and 3) the identity of the OCT3-expressing cells. B) While several studies have demonstrated OCT3-
mediated, corticosterone-sensitive monoamine clearance, key unanswered questions remain, including 4) the effects of 
corticosterone-induced inhibition on the physical spread and duration of released monoamines; and 5) the activation of 
low- and high-affinity monoamine receptors in target brain regions. 
 
4. Effects of corticosterone on dopamine clearance: in vivo studies 
The anatomical studies indicating that OCT3 is positioned to make important contributions to the clearance of 
released monoamines are consistent with ex vivo studies which have demonstrated OCT3-mediated, 
corticosterone-sensitive uptake of monoamines (Amphoux et al., 2006; Duan and Wang, 2010). This section 
summarizes studies in which we examined the effects of DAT inhibition (by cocaine or GRB12909) and OCT3 
inhibition (by corticosterone) on extracellular dopamine concentrations (by microdialysis) and clearance (using 
fast-scan cyclic voltammetry). These studies were focused on understanding the mechanisms by which stress, 
through elevation of glucocorticoid hormones, increases the reinstatement of cocaine seeking in rats with a 
history of cocaine self-administration. All of these studies examined the regulation of dopamine signaling in 
the nucleus accumbens, a region in which both DAT and OCT3 are expressed (Gasser et al., 2009), and an 
important site of dopamine action in the regulation of motivated behavior. Previous studies by Cui and 
colleagues provided convincing evidence that OCT3 plays a role in striatal dopamine clearance. These studies 
examined the effects of methamphetamine and the neurotoxin1-methyl-4-phenylpyridinium (MPP+), two 
dopamine-releasing agents, on extracellular dopamine levels in the dorsal striatum of wild-type and OCT3-
deficient mice. Increases in striatal extracellular dopamine induced by both methamphetamine and MPP+ were 
significantly larger, and lasted significantly longer, in OCT3-deficient mice than in wild-type mice (Cui et al., 
2009). 
Studies aimed at examining potential joint roles of OCT3 and DAT in regulating dopamine signaling tested the 
effects corticosterone and cocaine, alone and in combination, on extracellular dopamine concentrations in the 
rat nucleus accumbens (Graf et al., 2013). Rats were injected with vehicle or corticosterone (2 mg/kg, ip, a dose 
that approximates plasma concentrations reached in response to stress), followed by a low dose of cocaine 
(2.5 mg/kg), during the collection of dialysate samples from the nucleus accumbens. Corticosterone alone had 
no effect on basal extracellular dopamine concentrations. Surprisingly, low-dose cocaine alone had no effect on 
extracellular dopamine concentrations when preceded by vehicle injection. However, that same dose of cocaine 
caused significant increases in extracellular dopamine when it was preceded by an injection of corticosterone 
(Graf et al., 2013). These results are consistent with the hypothesis that corticosterone-induced potentiation of 
low-dose cocaine effects are due to inhibition of OCT3-mediated DA clearance, but because microdialysisdoes 
not allow direct quantification of dopamine clearance, the results may also be due to corticosterone-induced 
changes in the release or metabolism of dopamine. 
Direct assessment of the effects of corticosterone on DA clearance, required the use of in vivo fast-scan 
cyclic voltammetry (FSCV), an electrochemical technique that measures dopamine concentrations on a sub-
second time-scale, allowing detection of changes in dopamine release and clearance. In studies on anesthetized 
rats, we examined the effects of corticosterone, in the presence or absence of the DAT inhibitor GBR12909, on 
the clearance of dopamine released in the nucleus accumbens in response to electrical stimulation of the ventral 
tegmental area projection (Graf et al., 2013). After basal release and uptake parameters were collected, animals 
received an injection of the DAT inhibitor GBR12909, which significantly decreased the clearance (increased full 
width at half height (FWHH), apparent Km, and tau). After the effects of DAT blockade had stabilized, animals 
received an injection of vehicle or corticosterone (2 mg/kg, ip), and release and clearance parameters were 
again measured. Injection of corticosterone, but not vehicle, resulted in further decreases in dopamine 
clearance (further increases in FWHH, apparent Km, and tau), revealing for the first time in an in vivo study, the 
presence of corticosterone-sensitive, DAT-independent clearance of dopamine in vivo (Graf et al., 2013). 
Subsequent studies used FSCV to examine the effects of corticosterone on dopamine clearance in awake and 
behaving animals. In these studies, animals were treated with corticosterone (2 mg/kg, ip) or low-dose cocaine 
(2.5 mg/kg, ip), alone or in combination, and the amplitude and duration of naturally-occurring dopamine 
transients in the nucleus accumbens were measured. Surprisingly, administration of corticosterone alone, but 
not low-dose cocaine alone, significantly increased the duration and magnitude of spontaneous dopamine 
transients. Low-dose cocaine, while it had no effect on transient amplitude or duration alone, did induce robust 
increases in these measures when it was administered after corticosterone (Wheeler et al., 2017). These results 
indicate that, even in a DAT-rich region like the nucleus accumbens, corticosterone-induced decreases in DA 
clearance can be observed in the absence of DAT blockade, and that uptake1 (DAT-mediated) and uptake2 (likely 
OCT3-mediated) transport work in concert to shape dopamine signals in vivo. The relative contributions of 
uptake1and uptake2 processes to regulating specific monoamine signaling will likely vary regionally, depending 
on both the distributions of the transporters and the patterns of monoamine release. 
5. Corticosterone and the regulation of cocaine-seeking behavior: a role for 
OCT3 
The anatomical and neurochemical studies described above suggest that OCT3-mediated clearance may 
contribute significantly to the regulation of dopamine-dependent physiological processes, such as spike timing-
dependent plasticity (in cortical regions) and dopamine-dependent behavioral processes, including reward- and 
motivation-related behaviors. As it is inhibited by physiological concentrations of corticosterone, it represents a 
mechanism by which stress, via elevating glucocorticoids, may regulate brain function and behavior. Much work 
remains to clarify the contribution of OCT3 and other uptake2transporters in physiological and behavioral 
processes. The remainder of this review focuses on work we have done to examine a potential role of OCT3 in 
mediating glucocorticoid-induced alterations in cocaine-seeking behavior in rats. 
A series of behavioral studies examined the interaction of stress-levels of corticosterone with subthreshold 
doses of cocaine in rodent models of addiction (Graf et al., 2013; McReynolds et al., 2017). All studies involved 
training of rats or mice to associate lever pressing (rat self-administration) or a specific chamber 
(mouse conditioned place-preference (CPP)) with the administration of cocaine. Acquisition of the task is 
followed by a maintenance phase, in which drugself-administration is stably expressed, and then by extinction 
training, in which lever pressing or entry into the cocaine-paired chamber results in the administration of saline 
instead of cocaine. This leads to the extinction of the cocaine-conditioned behavior. Reinstatement of cocaine-
seeking behavior (pressing the lever in the absence of a cocaine reward (rat self-administration studies), or entry 
into the previously cocaine-paired chamber in the absence of drug reinforcement (mouse CPP studies)) in 
response to stress, low-dose cocaine, or corticosterone treatment is interpreted as drug-seeking behavior. 
The ability of corticosterone to influence reinstatement of drug-seeking behavior was tested in rats which had 
been trained to self-administer cocaine under short-access conditions (2 h daily access to the drug) (Graf et al., 
2013; McReynolds et al., 2017). Rats trained under short-access conditions, compared to those trained under 
long-access conditions, are resistant to stress- or cocaine-induced reinstatement of drug seeking behavior. 
Specifically, these animals do not resume lever pressing during reinstatement tests after either an injection of a 
low dose of cocaine (2.5 mg/kg), or exposure to 15 min of intermittent electric footshock stress. While neither of 
these two stimuli alone induces significant reinstatement of drug-seeking behavior, combination of the two (low 
dose cocaine preceded, 40 min earlier, by electric footshock) does (Graf et al., 2013; McReynolds et al., 2017). 
The effects of stress could be mimicked either by intraperitoneal injection of corticosterone at a dose that 
reproduces stress levels of the hormone (a treatment that did not by itself lead to reinstatement), or by bilateral 
injection of either corticosterone or the OCT3 inhibitor normetanephrine into the nucleus accumbens. The ability 
of corticosterone to potentiate low-dose cocaine-induced reinstatement was unaffected by pretreatment with 
RU-38486, an inhibitor of the glucocorticoid receptor, indicating that the corticosteroid effect was not mediated 
by the intracellular glucocorticoid receptor. The potentiating effect was blocked by intra-nucleus accumbens 
injection of fluphenazine, a DA receptor antagonist (Graf et al., 2013; McReynolds et al., 2017). Together, these 
behavioral studies indicate that corticosterone-induced potentiation of drug seeking is mediated by a GR-
independent mechanism involving local striatal dopamine signaling. In combination with the anatomical and 
neurochemical studies described above, these data are consistent with the hypothesis that corticosterone-
induced potentiation of reinstatement involves inhibition of OCT3-mediated clearance. However, due to the lack 
of mono-specific inhibitors of OCT3, these findings did not rule out the involvement of other cellular 
mechanisms. 
To more definitively demonstrate a role for OCT3 inhibition in corticosterone-induced potentiation of cocaine-
primed reinstatement, we examined the reinstatement of cocaine conditioned place preference in wild type 
mice, and in transgenic OCT3-deficient mice that express a truncated form of OCT3, and lack OCT3-mediated 
transport activity (Zwart et al., 2001). Both wild-type and OCT3 deficient mice acquired CPP to a high dose of 
cocaine (15 mg/kg) and extinguished drug-seeking behavior in a similar time course. Reinstatement of CPP was 
measured in response to a subthreshold dose of cocaine (0.93 mg/kg), which did not lead to significant 
reinstatement in wild-type mice. In wild-type mice, injection of either corticosterone or normetanephrine 
potentiated low-dose cocaine-induced reinstatement of CPP, but neither OCT3 inhibitor potentiated 
reinstatement in OCT3-deficient mice (McReynolds et al., 2017). Together, the rodent reinstatement studies 
coupled with the neurochemical measures indicate that the ability of stress and corticosterone to influence 
cocaine-seeking behavior is mediated, at least in part, by corticosterone-induced inhibition of dopamine 
clearance in the nucleus accumbens. 
The anatomical, neurochemical and behavioral studies described here suggest that uptake1 and 
uptake2 processes work together in a region- and context-specific manner to regulate the amplitude, duration 
and physical spread of dopamine signals and, thus, to determine the neuromodulatory influence of released 
dopamine. Although the studies described in this review focused on the role of OCT3 in 
regulating dopaminergic signaling, similar roles for OCT3 (and other uptake2transporters) in the regulation of 
noradrenergic, serotonergic and histaminergic neurotransmission likely exist. Indeed, a significant body of 
research has demonstrated roles for OCT3 and PMAT in serotonergic transmission (Baganz et al., 
2008, 2010; Dahlin et al., 2007). Similarly, this review focused on our studies examining OCT3-mediated 
dopamine transport as it relates to the neurochemical and behavioral effects of cocaine. There is a growing body 
of work examining roles for OCT3-mediated dopamine transport in the actions of other psychostimulantdrugs, 
including amphetamine (Mayer et al., 2018; Vialou et al., 2008) and methamphetamine (Cui et al., 2009; Kitaichi 
et al., 2003; Nakayama et al., 2007). Clearly, many questions remain to be answered about the roles played by 
OCT3 and the other uptake2 transporters in regulating monoamine signaling throughout the brain (Gasser and 
Daws, 2017). 
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